PRISM Mid-Day Movers: Robotic Medical Innovation and Disappointing Earnings Diverge Indices

Stock Information for NanoVibronix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NanoVibronix Inc.

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro(TM) in Early Alzheimer's Disease
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th
XPro(TM) Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer's Disease: Supported by Department of Defense
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.